Aster DM Quality Care Ltd (ASTERDM)
🎯 Key Takeaways
- Aster DM Quality Care Ltd is in a high-growth phase driven by the strategic merger of its core entities, creating a unified healthcare platform with 39 hospitals and 45,000 staff. Management is aggressively scaling super-specialty care, Tier 2/3 expansion, and high-margin segments like MVT and robotic surgery, targeting 24-25% EBITDA margins by FY28-FY29.
- Revenue grew 10.9% QoQ to ₹1,311 in Q1FY27.
- ⚠️ 1) Merger integration risks and execution delays in hospital expansions (e.g., new facilities in Trivandrum, Hyderabad, Sarjapur) could impact timelin
📖 The Story
Aster DM Quality Care Ltd is in a high-growth phase driven by the strategic merger of its core entities, creating a unified healthcare platform with 39 hospitals and 45,000 staff. Management is aggressively scaling super-specialty care, Tier 2/3 expansion, and high-margin segments like MVT and robotic surgery, targeting 24-25% EBITDA margins by FY28-FY29. The company is transitioning from integration costs to operational leverage, evidenced by strong revenue and EBITDA growth in Q1 FY27.
📰 What's Happening
The company completed its merger to form a unified platform, reporting Q1 FY27 revenue of INR 2,597 crores (+20% YoY) and EBITDA of INR 576 crores (+30% YoY), with EBITDA margin expanding 170 bps to 22.2%. Operational metrics show 2 million patients treated (13% YoY growth), 64% occupancy, 62% MVT revenue growth, and 80% robotics volume growth. Expansion plans include 4,170 new beds by 2029 (53% brownfield), with new hospitals operational by Jan 2027 (Trivandrum), Apr 2027 (Hyderabad), and H2 FY28 (Sarjapur). Management targets double-digit MVT contribution, oncology/robotic surgery growth, and 5-6% volume growth, supported by 7-8% ARPPU growth.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 1,197 | 1,186 | 1,182 | 1,311 |
| Operating Profit | 184 | 144 | 165 | 195 |
| OPM % | 15.3% | 12.1% | 14.0% | 14.9% |
| Net Profit | 121 | 59 | 154 | 29 |
| EPS | ₹2.13 | ₹1.02 | ₹2.72 | ₹0.31 |
Q1 FY27 revenue reached INR 2,597 crores, up 20% YoY, with EBITDA at INR 576 crores (+30% YoY) and EBITDA margin at 22.2% (up 170 bps). However, standalone Q1 FY26 results showed a sharp decline in profit before tax to INR 10.89 crores from INR 108.03 crores YoY, primarily due to INR 109.79 crores in merger-related exceptional items. This indicates the merger is temporarily compressing profitability, but operational metrics (e.g., 62% MVT revenue growth, 80% robotics volume growth) confirm accelerating momentum in high-margin segments post-merger.
🔮 Management Outlook & What's Next
Management targets 24-25% EBITDA margin by FY28-FY29, driven by synergy realization (10-15% incremental EBITDA), double-digit MVT contribution, and growth in oncology and robotic surgery. They expect volume growth of 5-6% and ARPPU growth of 7-8%, with new hospitals operational by Jan 2027 (Trivandrum), Apr 2027 (Hyderabad), and H2 FY28 (Sarjapur). Expansion is focused on Tier 2/3 markets in Kerala and Karnataka, with 53% of new beds planned as brownfield.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 500 | 500 | 518 | 518 |
| Reserves | 2,936 | 2,554 | 4,015 | 4,058 |
| Borrowings | 1,940 | 642 | 2,089 | 2,220 |
| Total Liabilities | 6,688 | 6,606 | 7,808 | 8,112 |
| Fixed Assets | 3,571 | 3,922 | 3,732 | 3,958 |
| Investments | 24 | 245 | 1,184 | 1,167 |
| Total Assets | 6,688 | 6,606 | 7,808 | 8,112 |
The balance sheet shows a significant increase in total assets to INR 8,112 crores as of Mar 2026, up from INR 6,606 crores in Mar 2025, driven by expansion investments. Borrowings rose to INR 2,220 crores from INR 642 crores YoY, reflecting capital expenditure for new hospitals and infrastructure. Equity and reserves increased to INR 4,576 crores (including INR 4,058 crores in reserves), indicating strong internal capital accumulation to fund growth without excessive leverage.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | +425 |
| Investing | +6,015 |
| Financing | -6,358 |
| Net Cash Flow | +82 |
👥 Shareholding Pattern
| Category | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|
| Promoters | 40.4% | 40.4% | 40.4% |
| FII | 18.5% | 17.2% | 10.5% |
| DII | 26.1% | 27.6% | 27.6% |
| Public | 4.1% | 3.9% | 3.7% |
| # Shareholders | 1,46,998 | 1,36,892 | 1,33,444 |
FII holdings increased substantially from 10.53% in Q1FY27 to 17.18% in Q4FY26, while DII holdings remained stable around 27%. Promoter holding is steady at 40.39%. The growing institutional interest (FII up 63% YoY in shareholding) suggests confidence in the merger-driven growth narrative, with 1,36,892 shareholders as of Q4FY26 indicating broadening retail participation.
⚖️ Peer Comparison — Healthcare
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| APOLLOHOSP | 1.27 L Cr | 60.9 | 22.1% | 22.9% | 0.60 |
| MANIPALHOS | 1.02 L Cr | — | — | — | 1.25 |
| MAXHEALTH | 98,594 | 67.6 | 14.4% | 13.6% | 0.27 |
| FORTIS | 70,211 | 67.0 | 13.3% | 10.8% | 0.29 |
| ASTERDM | 64,953 | 120.6 | 17.2% | 11.9% | 0.21 |
| MEDANTA | 39,538 | 71.0 | 21.9% | 16.3% | 0.10 |
| NH | 39,475 | 48.1 | 13.7% | 18.0% | 1.07 |
| LALPATHLAB | 32,366 | 46.5 | 29.6% | 21.8% | 0.00 |
| KIMS | 32,332 | 150.9 | 9.7% | 8.7% | 1.44 |
| POLYMED | 17,553 | 55.7 | 15.1% | 11.3% | 0.06 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Merger integration risks and execution delays in hospital expansions (e.g., new facilities in Trivandrum, Hyderabad, Sarjapur) could impact timelines and margins. 2) High capital expenditure for 4,170 new beds by 2029 may strain cash flows if occupancy or ARPPU growth falters. 3) Competitive intensity in Tier 2/3 markets could pressure pricing and occupancy, especially as rivals expand similarly.
📋 Recent Filings
-
🔴 Corporate Action 29 August 2026Aster DM Quality Care announced approval of a scheme to amalgamate its step-down subsidiaries KIMSHEALTH Executive Leisure Private Limited and Spicere...
-
🔴 Corporate Action 28 August 2026Aster DM Quality Care announced its subsidiary Chemistry Intermediate Holdings acquired 14.21% of Bangladesh's STS Holdings Limited for USD 44.1 milli...
-
🟡 voting results 26 August 2026Aster DM Quality Care Limited announced a postal ballot for shareholder approval of key appointments and resolutions, including Varun Shadilal Khanna ...
-
🔴 Financial Results 12 August 2026Aster DM Quality Care Limited reported Q1 FY27 revenue of INR 2,597 crores, up 20% YoY, with EBITDA at INR 576 crores, up 30% YoY, and EBITDA margin e...
-
Announcement 5 August 2026Aster DM Quality Care Limited announced its participation in a non-deal roadshow organized by Kotak Mahindra Capital from August 10-14, 2026, offering...
-
🟡 Board Meeting 5 August 2026The Board of Aster DM Quality Care Limited approved unaudited standalone and consolidated financial results for Q1 FY2026 ending 30 June 2026 during i...
-
Announcement 31 July 2026Aster DM Quality Care Limited announced an earnings conference call scheduled for 5 August 2026 at 6:00 PM IST to discuss unaudited Q1 FY27 results, i...
-
🔴 Announcement 30 July 2026Aster DM Quality Care Limited announced that CRISIL has assigned an AA+/Stable rating to its long-term bank facilities of ₹860.50 crores and an A1+ ra...
-
Announcement 23 July 2026Aster DM Healthcare Limited announced that its name will change to Aster DM Quality Care Limited effective July 28, 2026, as communicated by the Natio...
-
🟡 Board Meeting 13 July 2026Aster DM Quality Care announced the allotment of 35,35,51,410 new equity shares to eligible shareholders of the erstwhile Transferor Company following...
🧠 Analyst's Read
Aster DM is transitioning from merger integration to scalable growth, with Q1 FY27 results confirming strong top-line and operational momentum in high-margin segments. The key watchpoint is whether EBITDA margin expansion can accelerate toward the 24-25% target by FY28-FY29 as synergies materialize and new hospitals ramp up, amid ongoing capital intensity and integration execution.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when ASTERDM files new disclosures
Track ASTERDM filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track ASTERDM — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd